Abstract:AIMS:We conducted a presentation on an 84-year-old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR-CM). In order to establish its pathogenicity, we extensively investigated the biochemical and biophysical properties of the condition. METHODS AND RESULTS:Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly acknowledged progressive infiltrative cardiomyopathy that leads to heart failure and potentially fatal arrhythmias. Gaining a comprehensive understanding of the biochemical and biophysical characteristics of genetically mutated TTR proteins serves as the fundamental cornerstone for delivering precise medical care to individuals affected by ATTR. Laboratory assessments indicated a brain natriuretic peptide of 200.12 ng/L (normal range: 0-100 ng/L) and high-sensitivity cardiac troponin I of 0.189 μg/L (normal range: 0-0.1 μg/L). Echocardiography identified left atrial enlargement, symmetrical left ventricular hypertrophy (16 mm septal and 16 mm posterior wall), and a left ventricular ejection fraction of 56%. Cardiac-enhanced magnetic resonance imaging revealed subendocardial late gadolinium enhancement. Tc-99m-PYP nuclear scintigraphy confirmed grade 3 myocardial uptake, showing an increased heart-to-contralateral ratio (H/CL = 2.33). Genetic testing revealed a heterozygous missense mutation in the TTR gene (c.302C>T), resulting in an alanine-to-valine residue change (p. Ala81Val, following the first 20 residues of signal sequence nomenclature). Biochemical analysis of this variant displayed compromised kinetic stability in both the TTRA81V:WT (wild-type) heterozygote protein (half-life, t1/2 = 21 h) and the TTRA81V homozygote protein (t1/2 = 17.5 h). The kinetic stability fell between that of the TTRWT (t1/2 = 42 h) and the early-onset TTRL55P mutation (t1/2 = 4.4 h), indicating the patient's late-onset condition. Kinetic stabilizers (Tafamidis, Diflunisal, and AG10) all exhibited the capacity to inhibit TTRA81V acid- and mechanical force-induced fibril formation, albeit less effectively than with TTRWT. Chromatographic assessment of the patient's serum TTR tetramers indicated a slightly lower concentration (3.0 μM) before oral administration of Tafamidis compared with the normal range (3.6-7.2 μM). CONCLUSIONS:We identified a patient with hATTR-CM who possesses a rare TTRA81V mutation solely associated with cardiac complications. The slightly reduced kinetic stability of this mutation indicates its late-onset nature and contributes to the gradual progression of the disease.

The TTN p. Tyr4418Ter mutation causes cardiomyopathy in human and mice

Integrated multi-omics approach revealed TTNtv c.13254T>G causing dilated cardiomyopathy in mice

The Novel Mitochondrial 16S Rrna 2336T>C Mutation is Associated with Hypertrophic Cardiomyopathy

Titin truncations lead to impaired cardiomyocyte autophagy and mitochondrial function in vivo

Phenotype And Functional Analyses In A Transgenic Mouse Model Of Left Ventricular Noncompaction Caused By A Dtna Mutation

Dose-dependent Diastolic Dysfunction and Early Death in a Mouse Model with Cardiac Troponin Mutations.

The TNNI3 P.r186q Mutation is Responsible for Hypertrophic Cardiomyopathy Via Promoting FASN-stimulated Abnormal Fatty Acid Metabolism

Establishment of two cardiac-specific human cardiac troponin C mutation transgenic mice and comparative analysis

Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TNNI3 c.235C > T variant

CRISPR Activation Reverses Haploinsufficiency and Functional Deficits Caused by TTN Truncation Variants

The <i>LMNA </i>p.R541C mutation causes dilated cardiomyopathy in human and mice

Biochemical and Biophysical Properties of a Rare TTRA81V Mutation Causing Mild Transthyretin Amyloid Cardiomyopathy

Carrying both the heterozygous Myh6-R453C and Tnnt2-R92W mutations aggravate the hypertrophic cardiomyopathy phenotype in mice

Protective action of tetramethylpyrazine phosphate against dilated cardiomyopathy in cTnT R141W transgenic mice

Abnormal Splicing in the N-terminal Variable Region of Cardiac Troponin T Impairs Systolic Function of the Heart with Preserved Frank-Starling Compensation.

[Titin Gene Mutations in Chinese Patients with Dilated Cardiomyopathy].

Establishing a New Human Hypertrophic Cardiomyopathy-Specific Model Using Human Embryonic Stem Cells

Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias

Truncated titin is structurally integrated into the human dilated cardiomyopathic sarcomere

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells

LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice